<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>Ariad Pharmaceuticals, Inc. (ARIA): Don't Buy Ariad Pharmaceuticals Shares At These Levels - Seeking Alpha</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta http-equiv="P3P" content='CP="IDC DSP COR ADM DEVi TAIi PSA PSD IVAi IVDi CONi HIS OUR IND CNT"' />

 <script type="text/javascript">
 window.qbaka || (function(a,c){a.__qbaka_eh=a.onerror;a.__qbaka_reports=[];a.onerror=function(){a.__qbaka_reports.push(arguments);if(a.__qbaka_eh)try{a.__qbaka_eh.apply(a,arguments)}catch(b){}};a.onerror.qbaka=1;a.qbaka={report:function(){a.__qbaka_reports.push([arguments, new Error()]);},customParams:{},set:function(a,b){qbaka.customParams[a]=b},exec:function(a){try{a()}catch(b){qbaka.reportException(b)}},reportException:function(){}};var b=c.createElement("script"),e=c.getElementsByTagName("script")[0],d=function(){e.parentNode.insertBefore(b,e)};b.type="text/javascript";b.async=!0;b.src="//cdn.qbaka.net/reporting.js";"[object Opera]"==a.opera?c.addEventListener("DOMContentLoaded",d):d();qbaka.key="697c30d6de0ec176f16bc61dacb2980d"})(window,document);qbaka.options={autoStacktrace:1,trackEvents:1};
 </script>

<script type='text/javascript'>
try {
  window.external.msSiteModeCreateJumplist('SeekingAlpha - Read, Decide, Invest.');
  window.external.msSiteModeAddJumpListItem('Portfolio' ,
  'http://seekingalpha.com/account/portfolio?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Market Currents - Real-time stock market news updates' ,
  'http://seekingalpha.com/currents/all?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Investment Ideas' ,
  'http://seekingalpha.com/dashboard/investing_ideas?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Income Investing, Retirement Investing and Dividend Stocks' ,
  'http://seekingalpha.com/dashboard/investing_income?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('ETFs & Portfolio Strategy' ,
  'http://seekingalpha.com/dashboard/etfs?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('Macro View, Market Economy' ,
  'http://seekingalpha.com/dashboard/macro_view?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
  window.external.msSiteModeAddJumpListItem('My Email Alerts' ,
  'http://seekingalpha.com/account/email_preferences?source=ie_task',
  'http://static.cdn-seekingalpha.com/favicon.ico');
} catch (ex) {
}
</script>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name="msapplication-TileColor" content="#360000"/>
<meta name="msapplication-TileImage" content="http://static.cdn-seekingalpha.com/images/media_kit/71cdea92-2dc1-419d-8d62-f68b74c1eda8.png"/>
<meta name="msapplication-tooltip" content="Seeking Alpha - Read, Decide, Invest." />
<meta name="msapplication-starturl" content="http://seekingalpha.com?source=ie_task" />
<meta name="msapplication-task" content="name=Portfolio ;action-uri=http://seekingalpha.com/account/portfolio?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Market Currents - Real-time stock market news updates ;action-uri=http://seekingalpha.com/currents/all?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Investment Ideas ;action-uri=http://seekingalpha.com/dashboard/investing_ideas?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Income Investing, Retirement Investing and Dividend Stocks ;action-uri=http://seekingalpha.com/dashboard/investing_income?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=ETFs & Portfolio Strategy ;action-uri=http://seekingalpha.com/dashboard/etfs?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=Macro View, Market Economy ;action-uri=http://seekingalpha.com/dashboard/macro_view?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<meta name="msapplication-task" content="name=My Email Alerts ;action-uri=http://seekingalpha.com/account/email_preferences?source=ie_task;icon-uri=http://static.cdn-seekingalpha.com/favicon.ico" />
<!-- End IE9 Settings -->

<meta property="fb:admins" content="100006791796236" />

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@sa_popular">
<meta name="twitter:title" content="Don't Buy Ariad Pharmaceuticals Shares At These Levels">
<meta name="twitter:description" content="Ariad Pharmaceuticals Inc. (ARIA) delivered an early Christmas gift to investors on Friday morning, when the company announced that the FDA had approved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for its leukemia drug Iclusig (ponatinib) that allowed immediate resumption of its marketing and commercial distribution. Biotech investors might remember that ARIA shares imploded in early October, gapping down almost 70% before finally giving up about 90% of its valuation at the low of $2.15 in late-October. The implosion started after the company ">
<meta name='twitter:image' content='http://static1.cdn-seekingalpha.com/images/users_profile/000/891/106/big_pic.png?1360018065'><link rel="search" type="application/opensearchdescription+xml" href="/javascripts/seeking.xml" title="SeekingAlpha Search" />
<meta name="description" content="Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol Myers Squibb Co. (NYSE:BMY), Novartis AG (ADR) (NYSE:NVS): Don't Buy Ariad Pharmaceuticals Shares At These Levels" /><meta name="robots" content="noarchive" /><meta name="keywords" content="NASDAQ:ARIA, NYSE:BMY, NYSE:NVS" /><link rel="alternate" media="only screen and (max-width: 640px)" href="http://m.seekingalpha.com/article/1912401" /><meta name="original-source" content="http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels"><meta property="og:image" content="http://static.cdn-seekingalpha.com/uploads/2013/8/19/social_sa_logo.png" />
<meta property="og:title" content="Don't Buy Ariad Pharmaceuticals Shares At These Levels" />
<meta property="og:description" content="Ariad Pharmaceuticals Inc. (ARIA) delivered an early Christmas gift to investors on Friday morning, when the company announced that the FDA had approved revised U.S. Prescribing Information &#40;USPI&#41; and a Risk Evaluatio" />
<link rel="canonical" href="http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels" />
<script>
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
</script>

<link href="http://static3.cdn-seekingalpha.com/stylesheets/performance_layout_packaged.css?1388051886" media="screen" rel="stylesheet" type="text/css" /><link href="http://static3.cdn-seekingalpha.com/stylesheets/performance_layout_b_packaged.css?1388051886" media="screen" rel="stylesheet" type="text/css" /><link href="http://static.cdn-seekingalpha.com/stylesheets/article_packaged.css?1388051887" media="screen" rel="stylesheet" type="text/css" />
<script type="text/javascript">var siteon = false;</script>
<script type="text/javascript" src="/javascripts/siteon.js"></script>

<script type="text/javascript">
  var users_on_site='2,785,025';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (document.location.protocol == "https:") {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  } else if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="http://static.cdn-seekingalpha.com/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="http://seekingalpha.com/account/no_cookie_key"></scri'+'pt>');
  }
  
    (function(){
      var url='/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels';
      if (location.pathname!=url){
        if (window.history && history.replaceState) history.replaceState("", "", url+location.search);
        else location.href=url+location.search;
      }
    })();

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
  (function() {
    var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
    s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
    el.parentNode.insertBefore(s, el);
  })();
  var _sf_startpt=(new Date()).getTime(); // chartbeat code
  var is_pro = false;
  if (document.location.protocol == "https:") {
    document.write('<link rel="shortcut icon" type="image/ico" href="https://seekingalpha-a.akamaihd.net/favicon.ico" />')
  } else {
    document.write('<link rel="shortcut icon" type="image/ico" href="http://static.cdn-seekingalpha.com/favicon.ico" />')
  }
  
    
  var ASSET_HOSTS = ["http://static.cdn-seekingalpha.com","http://static1.cdn-seekingalpha.com","http://static2.cdn-seekingalpha.com","http://static3.cdn-seekingalpha.com"];
</script>

<script src="http://static3.cdn-seekingalpha.com/javascripts/common_packaged.js?1388051842" type="text/javascript"></script>
<script src="http://static3.cdn-seekingalpha.com/javascripts/common2_packaged.js?1388051845" type="text/javascript"></script><script src="http://static.cdn-seekingalpha.com/javascripts/common_article_packaged.js?1388051846" type="text/javascript"></script><script src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></script>
<script>
  if (SA.Data && SA.Data.Cache) {
    var adata = SA.Data.Cache.get('campaign_content');
  }
</script>

<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}
</script>

<script type="text/javascript">var NREUMQ=NREUMQ||[];NREUMQ.push(["mark","firstbyte",new Date().getTime()]);</script>      <script type="text/javascript">
  var adblock = false;
  try{
    GS_googleAddAdSenseService("ca-pub-1420150919334552");
    GS_googleEnableAllServices();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense1","adsense down");
  }
</script>
<script type="text/javascript">
  try{
      GA_googleAddSlot_sa('Article_120x30');
    GA_googleFetchAds();
  } catch(e) {
    adblock = true;
    Mone.event("Exception","adsense2","adsense down");
  }
</script>  </head>
    <body class="stretch_bg">
    <script>
  var ms_slug = '';
  var article_dashboards = '@investing-ideas@sectors@';
  var article_sectors_themes = '@long-ideas@us@biotechnology@healthcare@article@';
  var ratings_hash={};
  var ARTICLE_ID = 1912401;
  var ARTICLE_TYPE = "standard";
  var ARTICLE_LOCK = "";
  var author_slug = "gurufundpicks";
  var pticker_for_ads = "aria";
  var time_left;
  var lock_comments = false;
  var machine_cookie = readCookie('machine_cookie');
  var middle_version = ABTest.identity%10;
  var sector_name = "Healthcare";
  var sector_slug = "healthcare";
  try {
    window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');
  } catch (error) {}

</script>
<script>var mone_article_tags = "{bmy,nvs,aria};;;{healthcare};;;{long-ideas,us,biotechnology,investing-ideas,sa-exclusive};;;{gurufundpicks}"</script><script>var ord = Math.floor(Math.random()*1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (readCookie('sa_mobile') == '1') {
    var aHTML =[];
    aHTML.push('<div class="mobile_or_full_site">');
      aHTML.push('<span class="mobile_site" onclick="eraseCookie(\'sa_mobile\');top.location.reload()">Click here to view mobile site</span>');
      aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
</script>
<div class="promotion_cnt finance stars ipad_top">
  <div close="close"></div>
    <a onclick='Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_top_click");' href="/download-ipad-app?source=top_ipad_banner_large" class="promotion_video">
    <div class="ptext">
      <div class="ptext_t">Seeking Alpha Portfolio App for iPad</div>
      <div class="ptext_h">Finance</div>
      <div id='ipad_stars' class="stars stars_5"></div>
      <div class="rate">(<span class="rate_num" id="rate_num">1</span>)</div>
    </div>

    <div class="free"></div>
    <div class="sep"></div>
    <div class="ipad_screenshots"></div>
  </a>
</div>
<script>
  var ipadData;
  SeekingAlpha.Initializer.AddAfterLoad(function(){
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))){
      Mone.event("ipad_promotion_top","top_ipad_banner_large","ipad_promotion_displayed");
      ipadData = new SA.Data.iPad();
      ipadData.instanceName = "ipadData";
      var responseHandler = new Object();
      responseHandler.handleResponse = function(data){
        if (!data.averageUserRating) return;
        var stars = data.averageUserRating < 4 ? "4" : (data.averageUserRating+"").replace(".","");
        $("ipad_stars").className = "stars stars_"+stars;
        $("rate_num").innerHTML = data.userRatingCount;
      }
      ipadData.responseDelegate = responseHandler;
      ipadData.getData();
    }
    if (SA.Utils.Env.isIPad && !/3/.test(SA.Data.Cookies.get("user_devices"))) {
      $$("body")[0].addClassName('ipad_promotion')
    }
  });
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <span class="logo_old_h1"><a href="http://seekingalpha.com/" title="Seeking Alpha - Home Page" sasource="salogo"></a></span>
    
      <div class="item banner728x90" id='top_banner_728x90'>
          <script type="text/javascript">
            SA.Utils.Ads.add({el:$('top_banner_728x90'), HadCreated:false, size:'728x90', delta: null, NotSticky: true, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=728x90;x=x;tile=1;d=investing-ideas;t=long-ideas;aid=1912401;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=gurufundpicks;cnt=19;cnt=14;cnt=7;cnt=8;cnt=20;cnt=24;pr=aria;s=bmy;s=nvs;s=aria;'+dart_my_vocation_and_profiles()+'ord='+ord+'?', pos_key: '-t68r5wq0uxiz'});
            SA.Utils.Ads.run();
          </script>
      </div>
    
  </div>
  <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont">
      <ul id="navi" class="navi">
          <span id="old_dash">
        <li thistab='home' class="home">
          <a href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a href="http://seekingalpha.com/currents/all" sasource="headtabs">Market Currents</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_ideas'>
          <a href="http://seekingalpha.com/analysis/investing-ideas/all" sasource="headtabs">Investing Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='investing_income'>
          <a href="http://seekingalpha.com/analysis/investing-income/all" sasource="headtabs">Dividends &amp; Income</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='etfs'>
          <a href="http://seekingalpha.com/analysis/etf-portfolio-strategy/all" sasource="headtabs">ETFs</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='macro_view'>
          <a href="http://seekingalpha.com/analysis/macro-view/all" sasource="headtabs">Macro View</a>
          <span class="navi_right_corner">|</span>
        </li>
      </span>
        
        
        <span id="new_dash" style="display:none">
           <li thistab='home' class="home">
          <a style="font-size:14px" href="http://seekingalpha.com/" sasource="headtabs">Home</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='portfolio' class="portfolios">
          <a style="font-size:14px" href="http://seekingalpha.com/account/portfolio" sasource="headtabs">My Portfolio</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='market_news'>
          <a style="font-size:14px" href="http://seekingalpha.com/currents/all" sasource="headtabs">Breaking News</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='analysis'>
          <a style="font-size:14px" href="http://seekingalpha.com/analysis/all" sasource="headtabs">Latest Analysis</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='alpha_rich'>
          <a style="font-size:14px" href="http://seekingalpha.com/dashboard/alpha-rich" sasource="headtabs">Alpha-Rich Ideas</a>
          <span class="navi_right_corner">|</span>
        </li>
        <li thistab='stocktalks'>
          <a style="font-size:14px" href="http://seekingalpha.com/stocktalks/all" sasource="headtabs">StockTalk</a>
          <span class="navi_right_corner">|</span>
        </li>
        
        </span>
        
        <li thistab='alerts'>
          <a href="http://seekingalpha.com/real-time-alerts" sasource="headtabs">ALERTS</a>
            <span class="navi_right_corner">|</span>
          </li>
        <li thistab='pro' class="pro_tab">
            <a href="http://seekingalpha.com/account/pro" sasource="headtabs">PRO</a>
          </li>
        <li class="right_section">
          <div id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>
    <div class="rta_nav">
      <span class="rta_nav_wrap">
        <div id="rta_nav_close" onclick="SA.Promotion.Sticky.hide()" class="close_rta">&nbsp;</div>
        <div id="related_promo_container_rel_nav" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title_nav">This article was sent to <span id="promo_num_of_rta_rel_nav">5,418</span> people who get email alerts on <span class="replace_by_rel_slug">&nbsp;</span>.</div>
      <div class="title_sec">Which cover: new articles | breaking news | earnings results | dividend announcements</div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel_nav')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div>
  <div class="m_pop point_left" id="promotion_box_rel_nav" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel_nav" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph_nav">386,576</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel_nav', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader_nav" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel_nav" style="display:none;"></div>
</div>
                              </span>
    </div>
</div>
<script>
  if ((!window.is_pro || SA.Data.User.id()==3) && ((window.user_cookie && window.user_cookie.stocktalker) || ABTest.identity%10==0)){
    $('old_dash').hide();
    $('new_dash').show();
  }
</script>

  <script type="text/javascript">
    SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>
<div id="main_container" class="white_as_before ">
  <div id="content_wrapper" class="article_pages" itemscope itemtype="http://schema.org/Article">
    <img src="http://static.cdn-seekingalpha.com/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
    <div class="page_top">
      <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='search by symbol, author, keyword...' class="find_transcripts" />
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="http://www.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>
      <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="name">Don&#x27;t Buy Ariad Pharmaceuticals Shares At These Levels</span>
              </h1>
      <div id="article_info">
        
        <div class="article_info_pos">
          <span>Dec. 23, 2013  8:30 AM ET</span>
          <span class='print_hide'>|&nbsp;</span>
                              <span class="author_name_for_print">by: GuruFundPicks </span>

          <span id="second_line_wrapper" style="display:inline">
            <span id='title_article_comments'></span>
              <span class="print_hide">
                <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/aria" title='ARIAD Pharmaceuticals, Inc.' sasource='article_primary_about'>ARIA</a></span>,                 <span>Includes: </span><span id='about_stocks'><a href="/symbol/bmy" title='Bristol-Myers Squibb Company' sasource='article_about'>BMY</a>, <a href="/symbol/nvs" title='Novartis AG' sasource='article_about'>NVS</a></span>              </span>
          </spn>
       	</div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>    </div>
    <div class="cleaner"></div>
    <div id="main_content" class="no_big_gaps_main_content">
      
      <div id="article_body_container" class="no_big_gaps_article_body_container" style="float:right;">
        <div id="article_body" itemprop="articleBody">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
          <p>Ariad Pharmaceuticals Inc. (<a href='http://seekingalpha.com/symbol/aria' title='ARIAD Pharmaceuticals, Inc.'>ARIA</a>) delivered an early Christmas gift to investors on Friday morning, when the company announced that the <a href="http://seekingalpha.com/news-article/8519311-ariad-announces-u-s-resumption-of-marketing-and-commercial-distribution-of-iclusig-ponatinib-in-refractory-philadelphia-positive-leukemias">FDA had approved</a> revised U.S. Prescribing Information &#40;USPI&#41; and a Risk Evaluation and Mitigation Strategy (REMS) for its leukemia drug Iclusig (ponatinib) that allowed immediate resumption of its marketing and commercial distribution. Biotech investors might remember that ARIA shares imploded in early October, gapping down almost 70% before finally giving up about 90% of its valuation at the low of $2.15 in late-October. The implosion started after the company <a href="http://seekingalpha.com/news-article/7803582-ariad-announces-changes-in-the-clinical-development-program-of-iclusig">announced</a> on October 9th that the FDA placed a partial clinical hold on new patient enrollment in Iclusig clinical trials due to increased incidence of vascular toxicity observed in the updated clinical data from its pivotal PACE trial in chronic myeloid leukemia &#40;CML&#41; patients. This was followed by <a href="http://seekingalpha.com/news-article/7890872-ariad-announces-discontinuation-of-the-phase-3-epic-trial-of-iclusig-in-patients-with-newly-diagnosed-chronic-myeloid-leukemia">even more bad news</a> on Oct. 18th, when the FDA discontinued the CML trial, and then on Oct. 31st, when the FDA asked ARIA to <a href="http://seekingalpha.com/news-article/8021642-ariad-announces-temporary-suspension-of-iclusig-marketing-in-the-united-states">temporarily suspend</a> marketing and commercial distribution of Iclusig.</p> <p>Friday's positive news and powerful rally comes on the heels of a string of recent positive news that had brought ARIA shares back from the dead and up almost 200% from the lows to trade at $6.31, just before the FDA announcement on Friday at 10:10 AM. This included news on Nov. 22nd that the Committee for Human Medicinal Products &#40;CHMP&#41; of the European Medicines Agency &#40;EMA&#41; had <a href="http://seekingalpha.com/news-article/8276791-ariad-announces-positive-opinion-by-the-european-medicines-agency-on-the-continued-availability-of-iclusig-in-patients-with-leukaemias">rendered a positive opinion</a> on the continued availability of Iclusig in the European Union &#40;EU&#41; for use in patients in its authorized indications, while making specific recommendations to help minimize the risk of occlusive vascular events.</p> <p>ARIA shares mounted a strong rally in the three days after the CHMP announcement, doubling on the news to an intra-day high of $5.62 before settling back into the $4 to $5 range. The conclusions reached by the CHMP confirming the positive benefit-risk assessment of Iclusig, after considering the most recent safety information, bolstered Iclusig's chances for approval not just in the EU, but many also believed improved the prospects that the FDA would lift its suspension on Iclusig in the U.S., while making recommendations similar to the CHMP and issuing a black box warning label advising on the increased risk of cardiovascular events. Soon broker Stifel upgraded shares to a Buy from Hold, on December 10th, lifting its price target to $7, citing overwhelming support from doctors at the American Society of Hematology &#40;ASH&#41; meeting, that were universally positive on Iclusig's benefit/risk, and saw continued demand for it as a third line agent for chronic myeloid leukemia . Stifel was also spot-on in prognosticating a resumption of commercial distribution in the U.S. in 2014 with a black box warning label indicating increased risk of cardiovascular events.</p> <p>ARIA shares mounted another rally early last week, rising 63% from its $3.86 close on Monday to $6.31, just before the FDA announcement on Friday at 10:10 AM. This early week rally was triggered by news coming out of Europe that the European Medicines Agency (EMEA) put Iclusig on its <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2013/12/WC500158398.pdf" rel="nofollow">meeting agenda</a> for the week. ARIA shares made an intra-day high of $7.75 on Friday, before closing the day at $6.43. After the FDA announcement, Stifel raised their price target to $10, BMO raised their price target from $4 to $8, and equity research firm JMP Securities upgraded ARIA shares from 'Market Perform' to 'Outperform' rating.</p> <p>The resumption of Iclusig's marketing and commercial distribution in the U.S. is a triumph not just for ARIA shareholders and management, and Iclusig patients, but also for patient advocacy groups and doctors in general who lobbied on the patients behalf to reopen access to the drug. Iclusig, despite its blood clotting and associated cardiovascular risks, has been responsible for the cancers of many patients to go into remission for multiple years after being resistant to other drugs. It is this lobbying by patient advocacy groups and physicians that may have played a large role in bringing it back into the marketplace. We also have to laud ARIA pharmaceuticals for resolving complex issues with the FDA within just two months after suspension of the marketing and commercial distribution of Iclusig in the U.S.</p> <p>Now that ARIA shares are back from the dead, the question for shareholders is about the upside potential and downside risk of holding shares at these levels, as shares are up almost 200% from the lows of $2.15 just under two months ago.</p> <p>Iclusig is an expensive drug, priced at $115,000 per year. Even before Friday's announcement, under pressure from patient advocacy groups and physicians, FDA had instituted a special program under which it allowed patients who had benefited from the drug to continue taking it. Of the 640 patients that were receiving Iclusig at the end of October 2013, 260 continued to receive it even after the suspension through emergency and single-patient investigational new drug &#40;IND&#41; channels, that were reviewed and approved by the FDA on a case-by-case basis, and an additional 90 patients were approved to receive Iclusig after October using these same channels.</p> <p>Prior to October, in its <a href="http://www.sec.gov/Archives/edgar/data/884731/000119312513087814/d440641d10k.htm" rel="nofollow">latest SEC Form 10-K</a> filing for 2012, ARIA indicated that its market size included 2,500 patients in the U.S., 3,800 patients in Europe, and 600 patients in Japan with CML and Ph+ALL that would become resistant or intolerant to their existing tyrosine-kinase inhibitor (TKI) therapies, including Novartis' (<a href='http://seekingalpha.com/symbol/nvs' title='Novartis AG'>NVS</a>) Gleevec &amp; Bristol Myers Squibb's (<a href='http://seekingalpha.com/symbol/bmy' title='Bristol-Myers Squibb Company'>BMY</a>) Sprycel. However, under the more restrictive label, Iclusig may just become a drug of last resort when all the TKI options have been exhausted. Based on this revised label, ARIA expects that the target population in the U.S. drops to 1,300, and it is quite possible that this move by the FDA may be followed by other regulatory agencies, and if so, the target populations in Europe &amp; Japan may drop to 2,000 and 300 respectively. Taken together, this makes the overall market size for Iclusig at $414 mill., assuming pricing in the U.S., EU and Japan remains in the $115,000 range. Assuming the company reaches 80% market penetration in the next four years, and 5% increase in the market size every year, that would mean total sales of $403 mill. in 2017.</p> <p>ARIA operating expenses are currently about $80 mill. per quarter or $320 mill. annually, including almost equal parts R&amp;D and SG&amp;A expenses. Assuming that SG&amp;A expenses fall by a third, as ARIA plans to pare down half its staff, and that R&amp;D expenses drop by 20%, it would mean annual operating income of $168 million. Assuming a nominal 35% for taxes, we arrive at annual net income of $109 mill. or about 59 cents per share based on current 186 mill. shares. ARIA has cash reserves of $290 mill., and just $10 mill. in debt, and it burns through about $55 mill. per quarter. That burn rate is bound to drop with the reduction in operating expenses to the $55-$60 mill. range, which will last them until about mid to end-2015, when the company may need to raise more cash diluting existing shareholders. Given ARIA's low share price, assuming 20% dilution, ARIA could earn 49 cents per share in FY 2017. At current prices, it trades at 13 times possible earnings in FY 2017, four years out, which is steep, as if you assume a required return of 25% to account for biotech risk, and give it a multiple of 25 in FY 2017, it would put its current fair value at $5, below where the stock traded at the end-of-day on Friday.</p> <p>Making more optimistic assumptions, however, for example, Iclusig does not get a more restrictive label in EU &amp; Japan, so their total addressable patient population remains at 3,800 and 600, and assuming the same drug price at $115,000 per year per patient, we get a market size of $656 mill., and total sales of $637 mill. in 2017. Making similar assumptions about operating expenses and taxes, we arrive at net income of $262 mill. or $1.41 per share, which assuming 20% dilution, a 25 multiple to earnings in FY 2017 and a required return of 25% would give us a current fair value based on those assumptions of $12, almost twice the end-of-day close price on Friday of $6.43.</p> <p>Combining these two, it seems that at current prices, the market is assigning a 20% probability that Iclusig still gets to address the overall 4,400 patients in the EU &amp; Japan, instead of the reduced 2,300 patient population, in case those regulatory agencies take a cue from the FDA. Your decision on whether ARIA is a good investment at these levels will depend on what probability you assign to that outcome. We believe that a 20% probability seems reasonable, and consider ARIA shares fairly valued at current levels, and would not buy them here, until there is more positive news that comes out. This could include, for example, the outside possibility that Iclusig could still get to address the entire 2,500 patient population in the U.S., based on further clinical trials that tests Iclusig at lower doses, provided the lower dosage has similar efficacy and is safer at those levels. Also, it is conceivable that in such a case, clinical testing and approval could extend to a number of other cancer indications, including other leukemia, lung, gastrointestinal and thyroid cancers. This would lead to peak sales of Iclusig to well over $1 billion, warranting a market valuation back in the $3 bill. to $5 bill. range, but that seems very unlikely for now.</p> <p><b>Guru Fund Managers Were Bearish on ARIA Prior To October's Fall</b></p> <p>ARIA shares have been under heavy distribution by guru fund managers for each of the last five quarters in a row. From a peak of 9.77 mill. shares held by guru fund managers at the end of 2Q/2012, guru fund managers dumped 0.73 mill. shares, 3.80 mill. shares, 0.58 mill. shares, 4.20 mill. shares &amp; 0.14 mill. shares in 3Q/2012, 4Q/2012, 1Q/2013, 2Q/2013 &amp; 3Q/2013 respectively, ending with only 0.33 mill. shares at the end of the latest 3Q/2013. This is significant as in just over one year, guru fund managers dumped more than 96.6% of their holdings in the stock. Also, in the latest 3Q/2013, just prior to the catastrophic fall in October, three guru fund managers sold the stock and none bought it, and in the prior 2Q/2013, it was sold by eight guru fund managers while none bought it.</p> <p>The top guru fund seller during the latest 3Q/2013 was legendary billionaire investor Ken Griffin's Chicago-based hedge fund <a href="https://www.gurufundpicks.com/13f-ctd" rel="nofollow">Citadel Advisers</a> (click on the link for latest quarter summarized 13-F's), that sold 95,268 shares. Prior to that, the largest sellers were billionaire Stephen Cohen's hedge fund <a href="https://www.gurufundpicks.com/13f-sac" rel="nofollow">SAC Capital</a> that sold 6.82 mill. shares over the previous four quarters, Andreas Halvorsen's hedge fund <a href="https://www.gurufundpicks.com/13f-vik" rel="nofollow">Viking Global Investors</a> that sold 1.93 mill. shares in the prior three quarters, and Daniel Loeb's event-driven hedge fund <a href="https://www.gurufundpicks.com/13f-leb" rel="nofollow">Third Point LLC</a>, that sold 2.10 mill. shares in the prior four quarters.</p> <p>The vote of guru fund managers on their lack of confidence in ARIA's outlook stands in sharp contrast to that of mainstream Wall St. analysts, with 18 out of 22 ranking its shares at Buy/ Strong Buy prior to October's catastrophic news, with price targets of $24-$29. This included none other than mighty Goldman that put a $21 target on ARIA just last month, including upgrades also by Maxim Group, Summer Street, Oppenheimer, and Chardan Capital Markets, among others.</p> <p><em><a href="http://static.cdn-seekingalpha.com/uploads/2013/12/23/891106-1387801198889355-GuruFundPicks_origin.jpg" rel="lightbox" rel="nofollow"><img src="http://static.cdn-seekingalpha.com/uploads/2013/12/23/891106-1387801198889355-GuruFundPicks.jpg" hspace="6" vspace="6" /></a></em><br><em>(Click to enlarge)</em></p> <p>For anyone invested in the markets, however, it is common knowledge that biotech crashes like we saw on ARIA in October are all too common. An interest of ours is using the buying &amp; selling data of leading fund managers, as reported in their latest quarterly 13-F and daily SC 13D/G SEC filings, as an additional data-point to inform us on the probability of event outcomes, both positive and negative, and not just for biotech clinical trials, but for all stocks in the overall market. Our findings have revealed a <a href="https://www.gurufundpicks.com/how-use-consensuspicks-reports" rel="nofollow">strong correlation</a> between leading fund manager activity and the price direction for a stock over subsequent quarters, the most notable of which is the net selling we saw in Apple shares in the quarters preceding the decline. So, for investors that look for confirmation of their thesis from guru fund managers, their massive exit from the stock in each of the prior five quarters could have provided a clue as to what value these leading fund managers may have assigned to this biotech company's pipeline.</p>  
            <div id="article_source">Source: <a href="/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels?source=cc">Don&#x27;t Buy Ariad Pharmaceuticals Shares At These Levels</a></div>
            <!--googleoff: index-->
            <div id="article_body_top" class="disclosure_top" style="display:none;">
              <p><strong>Disclosure: </strong>I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. <span onclick='uncollapse()' id='more_button' style='cursor:pointer'><strong>(More...)</strong></span></p>
              <span id="business_disclosure" style="display:none"><p><strong>Business relationship disclosure:</strong> Business Relationship Disclosure: The article has been written by the Hedge and Mutual Fund Analyst at GuruFundPicks.com. GuruFundPicks.com is not receiving compensation for it (other than from Seeking Alpha). GuruFundPicks.com has no business relationship with any company whose stock is mentioned in this article. Use of GuruFundPicks&rsquo; research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that as of the publication date of any report or letter, GuruFundPicks, LLC, has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, GuruFundPicks intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders.</p></span>
            </div>
            <div style="clear:both"></div>
            <!--googleon: index-->
          
        </div>
        <script>SA.Pages.Article.handleDisclosures();</script>
        <div id="content_follow_up" class="underbar">
          <div id="follow_wrap">
              <div id="article_rta_bottom_container">
                <div id="related_promo_container_rel" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title">
      This article was sent to 
      <span id="promo_num_of_rta_rel">5,418</span>
      people who get email alerts on 
      <span class="replace_by_rel_slug">&nbsp;</span>.
    </div>
  </span>
  <div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel');">
    Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span>
  </div>
  <div class="m_pop point_left" id="promotion_box_rel" style="display:none;"></div>
</div>

<div id="related_promo_container_no_rel" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to
    <span id="dash_newsl_subscr_count_ph">
      386,576
    </span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel', 10727)">
      Get the Investing Ideas newsletter &raquo;
    </span>
    <span id="promo_no_rel_loader" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel" style="display:none;"></div>
</div>
<div class="fl mb10" id="roadblock_comment_unit" style="display:none">
  <div class="comments_top_area">
    <div class="comments_top_area_half">
      <div class="comments_top_area_add"><strong>Comments</strong>
      	<span id="general_comment_counter">(<span id="comments_block"></span>)</span>
      </div>
    </div>
    <div style="color:#FF6F00">
      This article has&nbsp;
      <span id="comments_block2"></span>
      &nbsp;comments. To read them or add your own, <a href="javascript:void(0)" onclick="rb=new roadblock('article crb');rb.register_show=comments_reg_show;comments_reg_show()">click here</a>.
    </div>
  </div>
</div>

<div id="techpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id="techpromo_button" onclick="SA.Pages.Article.sendTechPromoMail()"></div>
</div>

<div id="ipadpromo_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml90'>The #1 Portfolio App is Now on iPad!</div>
  <div id='sms_promo_line2' class='sms_line2 ml5 fwb mt10'>Get instant notifications & never miss a critical update on your stocks!</div>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt30"><div id="ipadpromo_button"></div></a>
  <a href="http://seekingalpha.com/download-ipad-app?source=article_ipad_app&kind=ipad" class="fl mt20"><div id="get_the_app"></div></a>
  <div id="ipadpromo_stars" class="fl mt15"></div>
</div>

<div id="store_container" style="display:none" class="fl mt30 mb30 w100">
  <div id='sms_promo_line1' class='sms_line1 ml25'>Which Seeking Alpha App is best for you?</div>
  <div class="mt15">
    <div class="ml25">
      <div class="fl"><input id="app_portfolio" type="checkbox"/></div>
      <div class="fl fwb ml10">Seeking Alpha Portfolio</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_tech" type="checkbox"/></div>
      <div class="fl fwb ml10">Tech Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_etf" type="checkbox"/></div>
      <div class="fl fwb ml10">ETF investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="ml25 mt15">
      <div class="fl"><input id="app_energy" type="checkbox"/></div>
      <div class="fl fwb ml10">Energy Investor</div>
      <div class="cb"></div>
    </div><div class="cb"></div>
    <div class="light-gray mt20 ml25">Email me a link to open from my phone:</div>
    <div class="ml25 mt5">
      <input id="email_to_download" type="text" style="width: 300px" class="fl" emailautofill="on" title="Email address" empty="Email address"/>
      <div class="bs-btn fl btn-primary ml10 btn-mini fwb" style="width: 70px;" onclick="SA.Pages.Article.sendLinkDownload()">Continue</div>
      <div class="cb"></div>
      <div class="red fs11" id="email_td_error"></div>
    </div>
  </div>
</div>

<div id="web_video_container" style="display:none" class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/LFNN6lhLtkk" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20" style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="ipad_video_container" style="display:none"  class="fl mt30 mb30">
  <iframe width="480" height="315" src="//www.youtube.com/embed/zEnMPGkjOnI" frameborder="0" allowfullscreen></iframe>
  <div class="fl mt20"  style="margin-left: 194px;"><a href="http://seekingalpha.com/download-app?source=vid_bottom_article">Get the app &raquo;</a></div>
</div>

<div id="portfolio_unit" style="display:none">
  <div id="portfolio_list_title" class="fwb fl mt3">PORTFOLIO</div>
<select id="portfolio_list" class="portfolio_list fl ml20" onchange="SA.Units.Portfolio.select(this)"></select>

<div class="cb"></div>

<div id="portfolio_stocks_container2" class="fl mt20">
  <div style="float:left;position:relative">
    <input type="text" id="portfolio_stocks_input" class="add_stock_text" placeholder="example: GLD, GOOG" style="height: 18px;" />
  </div>
  <span id="portfolio_stocks_btn" class="portfolio_stocks_btn ml5" onclick="SA.Units.Portfolio.addStocks()">Add Stocks</span>
  <span id="portfolio_stocks_error" class="portfolio_stocks_error" style="display:none"></span>
</div>

<div class="cb"></div>

<table id="portfolio_table" class="portfolio_table fl mt20">
  <thead><tr><th class="symbol">Symbol</th><th class="tc">Alerts</th><th class="tr">Price</th><th class="tr">Chg</th><th class="tr">% Chg</th></tr></thead>
  <tbody></tbody>
</table>

<div class="cb"></div>

<div id="portfolio_stocks_container" class="fl mt20">
  <div style="float:left;position:relative">
    <input type="text" id="portfolio_stocks_input" class="add_stock_text" placeholder="example: GLD, GOOG" style="height: 18px;" />
  </div>
  <span id="portfolio_stocks_btn" class="portfolio_stocks_btn ml5" onclick="SA.Units.Portfolio.addStocks()">Add Stocks</span>
  <span id="portfolio_stocks_error" class="portfolio_stocks_error" style="display:none"></span>
</div>

<div class="cb"></div></div>


              </div>
              <div id="article_rta_middle_container" style="display:none">
                <div id="related_promo_container_rel2" class="rta_bottom" style="display:none">
  <span class="title_wrap">
    <div class="rta_bottom_title" id="related_promo_title2">
      <span id="promo_num_of_rta_rel2">
         5,418
      </span>
         &nbsp;people received this article by email alert
         <span id="second_line_midelena"><br />Add your email to get alerts on <span class="replace_by_rel_slug">&nbsp;</span> too:</span>
    </div>
  </span>
  <div id="no_checkbox_midelena"><div class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('rel2')">Get email alerts on <span class="replace_by_rel_slug">&nbsp;</span><span class='rta_bottom_arrow'> &raquo;</span></div></div>
  <div class="m_pop point_left" id="promotion_box_rel2" style="display:none;"></div>
</div>
<div id="related_promo_container_no_rel2" class="rta_bottom newsletter" style="display:none">
  <div class="rta_bottom_title">
    This article was sent to <span id="dash_newsl_subscr_count_ph2">386,576</span> people who get the Investing Ideas newsletter.
    <span class="rta_bottom_lnk" onclick="SA.Pages.Article.relatedPromoAction('no_rel2', 10727)">Get the Investing Ideas newsletter &raquo;</span>
    <span id="promo_no_rel_loader2" style="display:none;"><img height="16" width="16" src="http://static3.cdn-seekingalpha.com/images/loader.gif" /></span>
  </div>
  <div class="m_pop" id="promotion_box_no_rel2" style="display:none;"></div>
</div>

              </div>
     		    <div id="article_tags" style="display:none">
              <div itemprop="articleSection" class="tagged_with">
                <span class="tagged_with_label">Tagged: </span><a href='/dashboard/investing_ideas' sasource='article_navigation'>Investing Ideas</a>, <a href='/analysis/investing-ideas/long-ideas' sasource='article_navigation'>Long Ideas</a>, <a href='/analysis/sectors/healthcare' sasource='article_navigation'>Healthcare</a>, <a href='/articles?filters=biotechnology' sasource='article_navigation'>Biotechnology</a>
              </div>
	          </div>
            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this article with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',1912401,'http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Don&#x27;t Buy Ariad Pharmaceuticals Shares At These Levels http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels?source=tweet $BMY $NVS $ARIA" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div onclick="alert('click')">
      <div id="span_fb_widget_share" style="display: none; background: ur('/images/facebook_small.gif');" class="fb-share-button fl ml-10 mt1" data-href="http://seekingalpha.com/article/1912401-dont-buy-ariad-pharmaceuticals-shares-at-these-levels?source=fb_share" data-type="button_count"></div>
    </div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'20px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '1912401'
        }
      });
    });

  </script>









  </script>
  </li>
</ul>            </div>
	          <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="more_by_auth" class="more_by_auth"></div>
            <div id="more_by_ticker" class="article_bottom_units"></div>
            <div id="temporary_place_holder" class="mt10"></div>
            <div class="cleaner"></div>
          </div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>
          <div class="cleaner"></div>
          <span class="article_submit_an_article_big" onclick="submit_your_article();"></span>
        </div>
      </div>
      <div id="secondary_ads" class="no_big_gaps_secondary_ads" style="float:right;">
        <div id="author_avatar">
    <div class="follow_sidebar">
      <script>var author_info_popup_timeout;</script>
<div id="author_info"> 
  <div class="author_page_tools" id="author_image_header">
    <div class="author_info_wrap">
      <a href="/author/gurufundpicks" class='this_is_a_author_pic' sasource="about_lpic"><img class="this_is_a_author_pic_img" align="center" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/891/106/big_pic.png?1360018065" width="115" height="115" alt="GuruFundPicks picture" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();" /></a>
 <div id="goto_edit_picture" class="goto_edit_picture" style='display:none'><span onclick="return goto_update_picture();" onmouseover="ShowAuthorInfo();" onmouseout="HideAuthorInfo();"></span></div>
        <div id="article_author_info" style="display:none;" onmouseover="clearAuthorInfoPopupTimeout();" onmouseout="HideAuthorInfo();">
          <div>
            <div class="followup_contributor_info">
  <div class="followup_contributor_info_title">
    <span>About the author: </span>
    <a href="/author/gurufundpicks" sasource="about_name">GuruFundPicks</a>
  </div>

  <div class="followup_contributor_info_on_author">
    <div class="followup_contributor_info_pic_cont">
      <div class="pic_cont">
        <div class="pic_contributor">
          <div class="the_pic">
              <a href="/author/gurufundpicks" sasource="about_pic"><img align="center" width="54" height="54" src="http://static1.cdn-seekingalpha.com/images/users_profile/000/891/106/big_pic.png?1360018065" alt="GuruFundPicks picture"/></a>
          </div>
        </div>
      </div>
    </div>
    <div class="followup_contributor_info_text">
      Follow us on Twitter for more updates (http://twitter.com/#GuruFundPicks or if already on Twitter, search for @GuruFundPicks). The two authors are co-managers of a family partnership long/short equity fund since 2001, with expertise in trading small-cap, micro-cap and nano-cap companies based on... <a href='/author/gurufundpicks' sasource='about_more'>More</a>
    </div>
    <div class="cleaner"></div>
	</div>
  <div class="followup_contributor_info_bottom_cnt">
    
    <div class="left_cnt">
      <ul class="followup_contributor_info_content_categories"><li>Company: <a rel='nofollow' target='_blank' href='http://www.gurufundpicks.com'>GuruFundPicks.com</a></li> <li>Blog: <a rel='nofollow' target='_blank' href='www.gurufundpicks.com'>GuruFundPicks's blog</a></li></ul>
    </div>
  </div>

  <div class="cleaner"></div>
</div>
<div class="followup_contributor_info_on_author_bottom"></div>

          </div>
        </div>
    </div>
    <a href="/author/gurufundpicks" itemprop="author" class="author_info_name" sasource="about_lname">GuruFundPicks</a>
    <div class="cleaner"></div>
    <div class="author_info_nav_border">
      <div class="author_info_nav">
        <ul class="the_author_info_nav">
          <li><a href='/author/gurufundpicks/articles'>Articles <span>(895)</span></a></li>
            <li>
                   <a href='/author/gurufundpicks/instablog'>Instablog
                     <span>(2)</span>
                   </a>
                 </li>                        <li>
                   <a href='/author/gurufundpicks/comments'>Comments <span>(74)</span></a>
                 </li>              <script>if (/stats viewer/.test(readCookie("user_perm"))) document.write("<li><a href='/account/authorboard/earnings?for_user_id=891106'>Earnings</a></li>");</script>
          <li><a href='/author/gurufundpicks'>Profile</a></li>        </ul>
      </div>
    </div>
    <div class="cleaner"></div>
    <div class="user_followers_following">
      <div class="user_followers">
        <a href="/author/gurufundpicks/followers">
          <span id="followers" class="number followers_number_891106 followers_number_gurufundpicks">2,101</span>
          <span class="text">Followers</span>
        </a>
      </div>
      <div class="user_followers">
        <a href="/author/gurufundpicks/following">
          <span id="followings" class="number">1</span>
          <span class="text">Following</span>
        </a>
      </div>
    </div>

    <div id="follow_this_user" class="follow_this_user"></div>
    <script>Follow.author_sidebar__follow_button_initiator('gurufundpicks')</script>
    <span class='author_info_send_message' onclick='Messaging.sendMessage("bdd9v20e", "Article Author ID Card Upper")'>Send Message</span>
    <div class="cleaner"></div>
  </div>
  <div class="follow_popup_wrapper">
      <div class="green_pop_wrapper" id="stop_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('stop_follow').style.display='none'"></span><p><span id="stop_follow_message"></span> GuruFundPicks</p><span class="stop_following" onclick="Follow.ajax_stop_follow_this_author(this, 'gurufundpicks')">Stop Following</span></div></div><div class="green_pop_wrapper" id="no_longer_follow" style="display:none"><div class="green_pop_top_arrow"></div><div class="green_pop"><span class="close_pop" onclick="$('no_longer_follow').style.display='none'"></span><p><span id="no_longer_message"></span> GuruFundPicks</p></div></div>  </div>
</div>
  <script>SeekingAlpha.Initializer.onDOMLoad(function (){Follow.setFfToElements($('followers'),$('followings'),17738)})</script>

    </div>
    <div class="cleaner"></div>
    About the author:
<ul>
<a target="_blank" href="http://www.gurufundpicks.com/"><img src="http://static.cdn-seekingalpha.com/uploads/2013/10/29/ad.gif" /></a>
</ul>
    </div>
          <div class="stickyad_wrapper">
            <div class="item banner160x600" id="fixed_banner160x600">
            </div>
          </div>
      </div>
    </div>
      <script>var page_ad_src = 'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1912401;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=gurufundpicks;cnt=19;cnt=14;cnt=7;cnt=8;cnt=20;cnt=24;pr=aria;s=bmy;s=nvs;s=aria;'+dart_my_vocation_and_profiles()+'ord='+ord+'?';</script>
  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
      <div class="item banner300x600">
        <script>add_js_to_ad_call('http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x250,300x600;x=x;tile=2;d=investing-ideas;pos=t;t=long-ideas;aid=1912401;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=gurufundpicks;cnt=19;cnt=14;cnt=7;cnt=8;cnt=20;cnt=24;pr=aria;s=bmy;s=nvs;s=aria;'+dart_my_vocation_and_profiles()+'ord='+ord+'?');</script>
      </div>
        <div id="alternative_title_container" class="mini_category data_currencies_table" style="display:none">
  <div class="sidebar_title_bk">
    <span class="sidebar_title_text" id="article_alternative_title"></span>			
  </div>
  <div id="symbol_alternative_tags" class="symbol_alternative_tags"></div>
  <div id="alternatives_pirsomet" class="alternatives_pirsomet" style="float:left;width:100%;"></div>
    <script type="text/javascript">
      ssga_always_display("Article_120x30", "http://9nl.it/i3eb/");
    </script>
  <div class="cleaner"></div>
</div>

<script type="text/javascript">
  symbol = "ARIA";
  new Ajax.Request('/articles/get_ajax_alternatives_by_symbol?symbol='+symbol, {
    asynchronous:true,
    evalScripts:true,
    method:'get',
    onComplete: function(transport) {
      if (transport.status == 200 && transport.responseText != 'failed') {
        response = transport.responseText.split("@@");
        symbolZiignight = new Ziignight('', 'SAlternative',"","symbolZiignight","symbol_alternative_tags","ETF");
        symbolZiignight.WorkJSON = eval(response[1]);
        symbolZiignight.addETF = false;
        symbolZiignight.pageType = 'Article';
        symbolZiignight.selectedSymbol = symbol;
        symbolZiignight.SAlternativePrint(-1,true);
        symbolZiignight.InsertEtfAlternativeSymbol(response[0]);
        $('article_alternative_title').innerHTML = response[0].toUpperCase() + " vs. ETF alternatives";
        $("alternative_title_container").style.display = "";
      }
    }
  });
</script>


      

        <div id="article_sidebar" class="article_sidebar">
          <div id="sidebar_down"><img src="http://static.cdn-seekingalpha.com/images/loader_recommended_articles.gif" width="64" height="64" class="loader"/></div>
        </div>

        <div class="cleaner"></div>
        <div class="stickyad_wrapper">
          <div class="item banner300x250" id="article_dart_sticky"></div>
        </div>
      <script>
          SA.Utils.Ads.add({el:$('article_dart_sticky'), HadCreated:false, size:'300x250', delta:50, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=300x251;x=x;tile=4;d=investing-ideas;pos=b;t=long-ideas;aid=1912401;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=gurufundpicks;cnt=19;cnt=14;cnt=7;cnt=8;cnt=20;cnt=24;pr=aria;s=bmy;s=nvs;s=aria;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
      </script>
  </div>
  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/14zm9" />
</div>

<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
        <div><span class="footer_title">TOP AUTHORS:</span>&nbsp;<a class="top_authors" href="http://seekingalpha.com/leader-board/opinion-leaders">The Opinion Leaders</a></div>
        <div class='top_boards'>
          <span class="footer_title">TOP USERS:</span>
          <a href="http://seekingalpha.com/leader-board/top-stocktalkers">StockTalkers</a> <span class="fl_dash">|</span>
          <a href="http://seekingalpha.com/leader-board/top-instablogs">Instablogs</a>
        </div>    
      </div>
      <div class="cleaner"></div>
    </div>
    
     <div class="footernav_share_buttons">
       <div class="fl">
         <div class="fb-like" data-href="http://www.facebook.com/pages/Seeking-Alpha/224867310939090" data-layout="button_count" data-show-faces="false" data-font="verdana" data-width="450">Follow us</div>
       </div>
      <div class="twitter_wrap ml0 fl"><a href="https://twitter.com/SAlphaTrending" class="twitter-follow-button twitter_share" data-show-count="false">Follow us</a></div>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/apps" sasource="footer">Mobile Apps</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2013 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>  <script type="text/javascript">
    Event.observe(window, 'scroll', check_positions);

    NEW_AD_DELTA = typeof(CHANGE_AD_DELTA) != "undefined" ? CHANGE_AD_DELTA : 0;
    SA.Utils.Ads.add({el:$('fixed_banner160x600'), HadCreated:false, size:'160x600', delta:NEW_AD_DELTA, info:'http://ad.doubleclick.net/adj/sek.investing-ideas/long-ideas;sz=160x600;x=x;tile=3;d=investing-ideas;t=long-ideas;aid=1912401;d=investing-ideas;d=sectors;t=long-ideas;t=us;t=biotechnology;t=healthcare;t=article;z=3;a=gurufundpicks;cnt=19;cnt=14;cnt=7;cnt=8;cnt=20;cnt=24;pr=aria;s=bmy;s=nvs;s=aria;'+dart_my_vocation_and_profiles()+'ord='+ord+'?'});
  </script>
<script>
  document.observe('dom:loaded', function(){
    if ($('article_source')) {$('article_source').hide();}
    if (!is_pro) {$$('.arich_promobox').each(function(o){o.show()})}
    SA.Pages.Article.primary = "aria";
    SA.Pages.Article.init({proSidebar: null});
    if (typeof(propromotion) != "undefined") {propromotion();}

    if (SA.Pages.Article.alpha_rich_article() || SA.Pages.Article.insiders_report_article()){
      update_pro_tracker(0,1,0,0);
    }

    if (location.href.match(/source=[a-z0-9_]*email[a-z0-9_]*/)) {createCookie('camefromrta',true);}
    var pagination_version = ABTest.identity%10;

    if (SA.Pages.Article.is_roadblock()){
      rb = new roadblock('article');
      rb.register_show = SA.Pages.Article.roadshow;
      Mone.event(rb.type,rb.source,"Half Article");
      SA.Pages.Article.cut_new(pagination_version);
    } else {
      if (!SA.Data.User.loggedIn() && (location.search.match(/[?&]source=(yahoo|nasdaq)/)) && !document.cookie.match(/\b(user_id|user_email|camefromrta)=/)) {
        SA.Pages.Article.hide_features_for_roadblock();
      }
    }
    if (/no_ads/i.test(window.location.href)) {SA.Pages.Article.strip_for_iframe()}

      SA.Pages.Article.btb();
  });
    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["bmy","nvs","aria"],"primarySlug":"aria","dashboard_id":10727,"dashboard_title":"Investing Ideas"});
    });
</script>
    <script src="http://static1.cdn-seekingalpha.com/javascripts/jspell_packaged.js?1388051858" type="text/javascript"></script>
<link href="http://static3.cdn-seekingalpha.com/stylesheets/footer_packaged.css?1388051887" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
  if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
    load_remote_script("http://static.cdn-seekingalpha.com/javascripts/sa.js?1388051829");
  if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
    load_remote_script("http://static1.cdn-seekingalpha.com/javascripts/tops.js?1388051545");
  Mone.renderedParams = {};
  SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('http://static1.cdn-seekingalpha.com/stylesheets/print.css?t=1388073554')});

  if (SA && SA.Data && SA.Data.User && SA.Data.User.loggedIn() && SA.Data.User.email() && SA.Data.User.email().match(/@seekingalpha.com/)){
    try{$('user_settings_pop').children[0].insert("<li class='mt10'><a href='javascript:void(0)' onclick='switch_status()'>PRO ON / OFF</a></li>");}catch(e){}
  }

  function switch_status(){
    new Ajax.Request('/authentication/get_menu', {
      asynchronous:true,
      method:'get',
      onComplete: function(transport) {
        eval(transport.responseJSON.code);
      }
    });
  }

  try{
    if (!siteon) {
      $('header').outerHTML += '<div id="outage_message">Most of Seeking Alpha is currently unavailable due to scheduled maintenance. Most published articles are still available for viewing. We apologize for any inconvenience.</div>';
      $('user_settings_wrapper').hide();
      $('outage_message').style.top = document.viewport.getDimensions().height -48 + "px";
    }
  } catch(e){}
</script>
<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>
<script src="http://static3.cdn-seekingalpha.com/javascripts/footer_packaged.js?1388051855" type="text/javascript"></script><div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
if (getURLParam("pu")=="all_holdings") $("tab_"+Portfolio.current_tab).click();  
}
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
var pubnub_test = '$|892165|19770181|17136652|12809951|52832|234601|946066|138138|119840|158117|3|6383|531163|9393711|4726401|1107427|2120371|2632411|';
try{
var auth = "|" + SA.Data.Cookies.get('user_id') + "|";
if (pubnub_test.indexOf(auth) > 0) {
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/sa_notify.js?149';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n)
var scriptElement_n = document.createElement("script");
scriptElement_n.defer = "defer";
scriptElement_n.src = 'http://static.cdn-seekingalpha.com/javascripts/utils/notify.js?151';
document.getElementsByTagName("head")[0].appendChild(scriptElement_n);
var scriptElement = document.createElement("script");
scriptElement.defer = "defer";
scriptElement.src = 'http://static.cdn-seekingalpha.com/javascripts/chat.js?149';
document.getElementsByTagName("head")[0].appendChild(scriptElement);
var fileref=document.createElement("link")
fileref.setAttribute("rel", "stylesheet")
fileref.setAttribute("type", "text/css")
fileref.setAttribute("href", "http://static.cdn-seekingalpha.com/stylesheets/chat.css?147")
document.getElementsByTagName("head")[0].appendChild(fileref)
}
} catch(e) {
}
</script>

<script type="text/javascript">if (typeof NREUMQ !== "undefined") { if (!NREUMQ.f) { NREUMQ.f=function() {
NREUMQ.push(["load",new Date().getTime()]);
var e=document.createElement("script");
e.type="text/javascript";
e.src=(("http:"===document.location.protocol)?"http:":"https:") + "//" +
  "js-agent.newrelic.com/nr-100.js";
document.body.appendChild(e);
if(NREUMQ.a)NREUMQ.a();
};
NREUMQ.a=window.onload;window.onload=NREUMQ.f;
};
NREUMQ.push(["nrfj","beacon-5.newrelic.com","c0370b1d43","334927,334964","cldeEUAJWgldEBsASkVRUwlXFRkWUA1D",0,55,new Date().getTime(),"","","","",""]);}</script>

<script type="text/javascript">
  var _memb_status, _ticker, _pv_count, _user_agent;
  if (SA.Data && SA.Data.User && SA.Data.User.loggedIn())
  {
    _memb_status = SA.Data.User.hasRTA() ? SA.Data.User.hasanApp() ? "reg_yes_email_yes_app" : "reg_yes_email_no_app" : SA.Data.User.hasanApp() ? "reg_no_email_yes_app" : "reg_no_email_no_app";
    _pv_count = "reg_already";
  } else {
    _memb_status = "non_reg";
    _pv_count = readCookie("pages_viewed");
    if(_pv_count){
      var pv_int = parseInt(_pv_count);
      if(_pv_count >= 1 && _pv_count <= 2) _pv_count = "no_reg_2_to_3";
      else if(_pv_count >= 3 && _pv_count <= 8) _pv_count = "no_reg_4_to_9";
      else if(_pv_count >= 9 && _pv_count <= 61) _pv_count = "no_reg_10_to_62";
      else if(_pv_count >= 62 && _pv_count <= 143) _pv_count = "no_reg_63_to_144";
      else _pv_count = "no_reg_144_plus";
    } else {
        _pv_count = "no_reg_1";
    }
  }
  var _selector = $('about_primary_stocks');
  _ticker = _selector ? _selector.select('a')[0].innerText : "no_ticker";
  if (SA.Utils && SA.Utils.Env && SA.Utils.Env.isIPad) _user_agent = "ipad";
  else if(SA.Utils.Env.mobileOS) _user_agent = "mobile";
  else _user_agent = "desktop";
  var google_tag_params = {
    memb_status: _memb_status,
    tickers: _ticker,
    pv_count: _pv_count,
    user_agent: _user_agent
  };

  /* <![CDATA[ */
  var google_conversion_id = 976471699;
  var google_conversion_label = "yEDNCN3OkAoQk43P0QM";
  var google_custom_params = window.google_tag_params;
  var google_remarketing_only = true;
  /* ]]> */
</script>
<script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js">
</script>
    <div class="cleaner"></div>
  </body>
</html>
